In a closely watched case, Allergan (AGN) won a lawsuit in which it used a novel legal theory to blunt competition from a compounding pharmacy, although the victory came at a price.
Here’s the backstory: The drug maker accused Imprimis Pharmaceuticals of falsely advertising compounded versions of its eye treatments for cataracts and glaucoma because the smaller company failed to follow federal regulations.
About the Author Reprints
